Skip to main content
رجوع
BMY logo

Bristol-Myers Squibb Company

جودة البيانات: 100%
BMY
NYSE Healthcare Drug Manufacturers - General
KWD 57.00
▼ KWD 0.48 (-0.84%)
القيمة السوقية: 116.08B
نطاق اليوم
KWD 57.00 KWD 58.25
نطاق 52 أسبوعًا
KWD 42.52 KWD 62.89
حجم التداول
7,768,761
متوسط 50 يوم / 200 يوم
KWD 58.53 / KWD 50.38
الإغلاق السابق
KWD 57.48

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 16.5 0.4
P/B 6.3 2.9
ROE % 40.5 3.7
Net Margin % 14.6 3.8
Rev Growth 5Y % 1.0 10.0
D/E 2.6 0.2

Insider Trading Activity

19 transactions
Date Insider Type Shares Price Value
Feb 1, 2026
YALE PHYLLIS R
Director
 grant 3,996 KWD 55.050 KWD 219,980
Feb 1, 2026
Haller Julia A
Director
 grant 3,996 KWD 55.050 KWD 219,980
Feb 1, 2026
Samuels Theodore R. II
Director
 grant 3,996 KWD 55.050 KWD 219,980
Feb 1, 2026
Rice Derica W
Director
 grant 3,996 KWD 55.050 KWD 219,980
Dec 31, 2025
Rice Derica W
Director
 grant 695 — —
Dec 31, 2025
Samuels Theodore R. II
Director
 grant 927 — —
Dec 31, 2025
McMullen Michael R.
Director
 grant 649 — —
Oct 2, 2025
Gallman Cari
EVP, General Counsel
 other 11,448 — —
Sep 1, 2025
Short Bartie Wendy
EVP, Corporate Affairs
 other 3,102 — —
Aug 2, 2025
Short Bartie Wendy
EVP, Corporate Affairs
 other 1,476 — —
Aug 2, 2025
Short Bartie Wendy
EVP, Corporate Affairs
 sell 378 KWD 44.230 KWD 16,719
Aug 1, 2025
Massacesi Cristian
EVP,Chief Med Offr,Head of Dev
 grant 204,691 — —
Jun 30, 2025
Arduini Peter J
Director
 grant 729 — —
Jun 30, 2025
McMullen Michael R.
Director
 grant 728 — —
Jun 3, 2025
BOERNER CHRISTOPHER S.
Chief Executive Officer
 other 125,440 — —
Jun 3, 2025
Short Bartie Wendy
EVP, Corporate Affairs
 other 19,414 — —
Apr 1, 2025
Shanahan Karin
EVP, Glob. Prod. Dev. & Supply
 other 8,304 — —
Mar 31, 2025
McMullen Michael R.
Director
 grant 512 KWD 60.990 KWD 31,227
Mar 31, 2025
Arduini Peter J
Director
 grant 553 KWD 60.990 KWD 33,727

النقاط الرئيسية

Revenue grew 0.96% annually over 5 years — modest growth
ROE of 40.53% indicates high profitability
Debt/Equity of 2.55 — high leverage
Generating 12.85B in free cash flow
Cash machine — converts 182.12% of earnings into free cash flow
Capital efficient — spends only 2.72% of revenue on capex

النمو

Revenue Growth (5Y)
0.96%
Revenue (1Y)-0.22%
Earnings (1Y)N/A
FCF Growth (3Y)0.76%

الجودة

Return on Equity
40.53%
ROIC14.51%
Net Margin14.63%
Op. Margin26.34%

الأمان

Debt / Equity
2.55
Current Ratio1.26
Interest Coverage8.41

التقييم

P/E Ratio
16.46
P/B Ratio6.28
EV/EBITDA12.05
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0.22% Revenue Growth (3Y) 3.48%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -6.25%
Revenue Growth (5Y) 0.96% Earnings Growth (5Y) 0.21%
Profitability
Revenue (TTM) 48.19B Net Income (TTM) 7.05B
ROE 40.53% ROA 7.83%
Gross Margin 67.65% Operating Margin 26.34%
Net Margin 14.63% Free Cash Flow (TTM) 12.85B
ROIC 14.51% FCF Growth (3Y) 0.76%
Safety
Debt / Equity 2.55 Current Ratio 1.26
Interest Coverage 8.41 Dividend Yield 0.05%
Valuation
P/E Ratio 16.46 P/B Ratio 6.28
P/S Ratio 2.41 PEG Ratio -0.09
EV/EBITDA 12.05 Dividend Yield 0.05%
Market Cap 116.08B Enterprise Value 153.01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 48.19B 48.30B 45.01B 46.16B 46.39B
Net Income 7.05B -8.95B 8.03B 6.33B 6.99B
EPS (Diluted) 3.45 -4.41 3.86 2.95 3.12
Gross Profit 32.60B 27.43B 25.36B 26.49B 26.76B
Operating Income 12.70B 9.66B 8.47B 9.27B 9.54B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 90.04B 92.60B 95.16B 96.82B 109.31B
Total Liabilities 71.53B 76.22B 65.67B 65.70B 73.31B
Shareholders' Equity 18.47B 16.34B 29.43B 31.06B 35.95B
Total Debt 47.14B 51.20B 41.46B 40.72B 45.60B
Cash & Equivalents 10.21B 10.35B 11.46B 9.12B 13.98B
Current Assets 29.39B 29.78B 31.77B 27.27B 33.26B
Current Liabilities 23.42B 23.77B 22.26B 21.89B 21.87B